Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4161 - Follow-up and recurrence in resected gastroenteropancreatic neuroendocrine tumours: A population-based study

Date

10 Sep 2017

Session

Poster display session

Presenters

David Chan

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

D. Chan1, E. Segelov2, L. Moody3, N. Liu4, H. Fischer4, P. Austin4, S. Singh1

Author affiliations

  • 1 Medical Oncology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 2 Medical Oncology, Monash University and Monash Health, Melbourne/AU
  • 3 Ihpme, University of Toronto, Toronto/CA
  • 4 Biostatistics, Institute of Clinical Evaluative Sciences, Toronto/CA
More

Resources

Abstract 4161

Background

Neuroendocrine tumours (NETs) are uncommon. Little data exist to guide follow-up in resected disease, with no consensus regarding the optimal follow-up frequency or modality. Follow-up imaging regimens are extrapolated from other gastrointestinal tumours. As NETs are heterogeneous, this may result in both over-use and underuse of investigations in patients.

Methods

A population-based retrospective cohort study using linked data from the Institute for Clinical Evaluative Sciences and the Ontario Cancer Registry (capturing more than 99% of incident cases in Ontario) was conducted to evaluate patients diagnosed with gastroenteropancreatic NETs in Ontario, Canada from 1994 to 2012. Recurrence-free survival and the frequency of cross sectional imaging (abdominal computed tomography (aCT), magnetic resonance imaging (aMRI) and ultrasound (aUS)) were the main outcomes.

Results

Nine hundred and thirty-six patients were identified with median follow-up 47 months. The mean age was 59, 51% were female, and distribution of primary cancers was: small intestine 47%, pancreas 20%, large intestine 21%, rectum 6.4%, stomach 6.0%. The median survival time to a composite outcome of recurrence or death was 7.2 years, and 9.5 years if censoring on death. The cumulative incidence of recurrence was 8.4% (95% CI 6.8% to 10.3%) within one year, 33.7% (95% CI 30.4% to 36.9%) within five years, and 48.5% (95% CI 44.4% to 52.4%) within 10 years. The rate of recurrence significantly increased with age (HR = 1.529 for age 50-70 compared to 

Conclusions

Unlike colon cancer, significant numbers of NETs recur between 5-10 years after curative surgical resection. These data support the lengthening of follow-up for resected NETs to a minimum of 10 years. Future research should focus on the impact of imaging on early detection of recurrence and survival outcomes.

Clinical trial identification

Legal entity responsible for the study

Sunnybrook Research Institute

Funding

AGITG

Disclosure

D. Chan: Travel support from Novartis; honoraria from Ipsen. E. Segelov: Honoraria from Roche, Bayer, Ipsen and Pfizer; research funding from Merck Serono and Ipsen; travel support from Roche and Ipsen. S. Singh: Honoraria and travel funding from Ipsen, Pfizer and Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.